
Ann Marshak-Rothstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8203922/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The FasLane to ocular pathology—metalloproteinase cleavage of membraneâ€bound FasL determines FasL function. Journal of Leukocyte Biology, 2021, 110, 965-977.	1.5	2
2	cGAS-STING Pathway Does Not Promote Autoimmunity in Murine Models of SLE. Frontiers in Immunology, 2021, 12, 605930.	2.2	30
3	Dysbiosis exacerbates colitis by promoting ubiquitination and accumulation of the innate immune adaptor STING in myeloid cells. Immunity, 2021, 54, 1137-1153.e8.	6.6	46
4	Role of Interferonâ€Î³â€"Producing Th1 Cells in a Murine Model of Type I Interferon–Independent Autoinflammation Resulting From DN ase II Deficiency. Arthritis and Rheumatology, 2020, 72, 359-370.	2.9	9
5	Interplay of Cyclic GMP-AMP Synthase/Stimulator of IFN Genes and Toll-Like Receptor Nucleic Acid Sensing Pathways in Autoinflammation and Abnormal Bone Formation due to DNasell-Deficiency. Viral Immunology, 2020, 33, 246-249.	0.6	2
6	The role of nucleic acid sensors and type I IFNs in patient populations and animal models of autoinflammation. Current Opinion in Immunology, 2019, 61, 74-79.	2.4	5
7	Molecular pattern recognition in peripheral B cell tolerance: lessons from age-associated B cells. Current Opinion in Immunology, 2019, 61, 33-38.	2.4	18
8	A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma. Journal of Neuroinflammation, 2019, 16, 184.	3.1	87
9	Hierarchy of clinical manifestations in SAVI N153S and V154M mouse models. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7941-7950.	3.3	83
10	Cross-Reactive Antigen Expressed by B6 Splenocytes Drives Receptor Editing and Marginal Zone Differentiation of IgG2a-Reactive AM14 VI®8 B Cells. Journal of Immunology, 2019, 203, 2055-2062.	0.4	1
11	Soluble Fas ligand blocks destructive corneal inflammation in mouse models of corneal epithelial debridement and LPS induced keratitis. Experimental Eye Research, 2019, 179, 47-54.	1.2	13
12	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus—An Ongoing Need for International Consensus and Collaborations. Journal of Investigative Dermatology, 2019, 139, 270-276.	0.3	18
13	Dendritic Cell RIPK1 Maintains Immune Homeostasis by Preventing Inflammation and Autoimmunity. Journal of Immunology, 2018, 200, 737-748.	0.4	30
14	The Chaperone UNC93B1 Regulates Toll-like Receptor Stability Independently of Endosomal TLR Transport. Immunity, 2018, 48, 911-922.e7.	6.6	92
15	Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus–like inflammation. Journal of Clinical Investigation, 2018, 128, 2966-2978.	3.9	41
16	STING Contributes to Abnormal Bone Formation Induced by Deficiency of DNase II in Mice. Arthritis and Rheumatology, 2017, 69, 460-471.	2.9	27
17	Taking the STING out of TLR-driven autoimmune diseases: good, bad, or indifferent?. Journal of Leukocyte Biology, 2017, 101, 121-126.	1.5	12
18	Autoreactive helper T cells alleviate the need for intrinsic TLR signaling in autoreactive B cell activation. ICI Insight, 2017, 2, e90870.	2.3	13

#	Article	IF	CITATIONS
19	A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens. Journal of Clinical Investigation, 2017, 127, 1651-1663.	3.9	75
20	TLR9 Deficiency Leads to Accelerated Renal Disease and Myeloid Lineage Abnormalities in Pristane-Induced Murine Lupus. Journal of Immunology, 2016, 197, 1044-1053.	0.4	51
21	Autoimmunity – promoting and stabilizing innate immunity â€~UNWUCHT'. Immunological Reviews, 2016, 269, 7-10.	2.8	6
22	Overexpression of Soluble Fas Ligand following Adeno-Associated Virus Gene Therapy Prevents Retinal Ganglion Cell Death in Chronic and Acute Murine Models of Glaucoma. Journal of Immunology, 2016, 197, 4626-4638.	0.4	43
23	Synergy between Hematopoietic and Radioresistant Stromal Cells Is Required for Autoimmune Manifestations of DNase Ilâ^'/â^'IFNaRâ^'/â^' Mice. Journal of Immunology, 2016, 196, 1348-1354.	0.4	11
24	Toll-Like Receptor-Dependent Immune Complex Activation of B Cells and Dendritic Cells. Methods in Molecular Biology, 2016, 1390, 249-272.	0.4	11
25	Suppression of systemic autoimmunity by the innate immune adaptor STINC. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E710-7.	3.3	139
26	Cutting Edge: AIM2 and Endosomal TLRs Differentially Regulate Arthritis and Autoantibody Production in DNase Il–Deficient Mice. Journal of Immunology, 2015, 194, 873-877.	0.4	88
27	Cutting Edge: DNase II Deficiency Prevents Activation of Autoreactive B Cells by Double-Stranded DNA Endogenous Ligands. Journal of Immunology, 2015, 194, 1403-1407.	0.4	51
28	Cell-Intrinsic Expression of TLR9 in Autoreactive B Cells Constrains BCR/TLR7-Dependent Responses. Journal of Immunology, 2015, 194, 2504-2512.	0.4	54
29	IL-21 Promotes Pulmonary Fibrosis through the Induction of Profibrotic CD8+ T Cells. Journal of Immunology, 2015, 195, 5251-5260.	0.4	40
30	Nucleic Acid–Sensing Receptors: Rheostats of Autoimmunity and Autoinflammation. Journal of Immunology, 2015, 195, 3507-3512.	0.4	68
31	Gadolinium-based compounds induce NLRP3-dependent IL-1Î ² production and peritoneal inflammation. Annals of the Rheumatic Diseases, 2015, 74, 2062-2069.	0.5	37
32	An unexpected role for RNA-sensing toll-like receptors in a murine model of DNA accrual. Clinical and Experimental Rheumatology, 2015, 33, S70-3.	0.4	3
33	Cutting Edge: The UNC93B1 Tyrosine-Based Motif Regulates Trafficking and TLR Responses via Separate Mechanisms. Journal of Immunology, 2014, 193, 3257-3261.	0.4	37
34	The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation. Nature Immunology, 2014, 15, 727-737.	7.0	651
35	Editorial overview. Current Opinion in Immunology, 2013, 25, 667-669.	2.4	4
36	The role of Bruton's tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells. Journal of Leukocyte Biology, 2013, 94, 865-875.	1.5	12

#	Article	IF	CITATIONS
37	Role of type I interferons in the activation of autoreactive B cells. Immunology and Cell Biology, 2012, 90, 498-504.	1.0	182
38	Activation of Autoreactive B Cells by Endogenous TLR7 and TLR3 RNA Ligands. Journal of Biological Chemistry, 2012, 287, 39789-39799.	1.6	55
39	Cutting Edge: FAS (CD95) Mediates Noncanonical IL- $1\hat{l}^2$ and IL-18 Maturation via Caspase-8 in an RIP3-Independent Manner. Journal of Immunology, 2012, 189, 5508-5512.	0.4	254
40	Selective binding of anti-DNA antibodies to native dsDNA fragments of differing sequence. Immunology Letters, 2012, 143, 85-91.	1.1	21
41	Opposing Roles for Membrane Bound and Soluble Fas Ligand in Glaucoma-Associated Retinal Ganglion Cell Death. PLoS ONE, 2011, 6, e17659.	1.1	77
42	Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Seminars in Immunology, 2011, 23, 106-112.	2.7	172
43	Beyond transitional selection: New roles for BLyS in peripheral tolerance. Drug Development Research, 2011, 72, 779-787.	1.4	13
44	FcγRIIB regulation of BCR/TLRâ€dependent autoreactive Bâ€cell responses. European Journal of Immunology, 2010, 40, 2692-2698.	1.6	21
45	Poly(I:C) Drives Type I IFN- and TGFβ-Mediated Inflammation and Dermal Fibrosis Simulating Altered Gene Expression in Systemic Sclerosis. Journal of Investigative Dermatology, 2010, 130, 2583-2593.	0.3	121
46	IFN Regulatory Factor 5 Is Required for Disease Development in the <i>FcγRIIBâ^'/â^'Yaa</i> and <i>FcγRIIBâ^'/â^'</i> Mouse Models of Systemic Lupus Erythematosus. Journal of Immunology, 2010, 184, 796-806.	0.4	91
47	Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity, 2010, 43, 76-83.	1.2	103
48	RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity, 2010, 43, 103-110.	1.2	48
49	Differential Cytokine Production and Bystander Activation of Autoreactive B Cells in Response to CpG-A and CpG-B Oligonucleotides. Journal of Immunology, 2009, 183, 6262-6268.	0.4	39
50	Murine B Cell Response to TLR7 Ligands Depends on an IFN-β Feedback Loop. Journal of Immunology, 2009, 183, 1569-1576.	0.4	119
51	Requirement for DNA CpG Content in TLR9-Dependent Dendritic Cell Activation Induced by DNA-Containing Immune Complexes. Journal of Immunology, 2009, 183, 3109-3117.	0.4	104
52	DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Faslpr/lpr mice in vivo. Arthritis Research and Therapy, 2009, 11, R79.	1.6	48
53	Toll-Like Receptor-Dependent Immune Complex Activation of B Cells and Dendritic Cells. Methods in Molecular Biology, 2009, 517, 363-380.	0.4	18
54	Autoreactive B Cells Discriminate CpG-Rich and CpG-Poor DNA and This Response Is Modulated by IFN-α. Journal of Immunology, 2008, 181, 5875-5884.	0.4	78

#	Article	IF	CITATIONS
55	Hierarchical requirement for CpG Motifs in dendritic cell activation induced by DNAâ€containing immuneâ€complexes. FASEB Journal, 2008, 22, 668.23.	0.2	0
56	Murine Dendritic Cell Type I IFN Production Induced by Human IgG-RNA Immune Complexes Is IFN Regulatory Factor (IRF)5 and IRF7 Dependent and Is Required for IL-6 Production. Journal of Immunology, 2007, 178, 6876-6885.	0.4	157
57	Functional Outcome of B Cell Activation by Chromatin Immune Complex Engagement of the B Cell Receptor and TLR9. Journal of Immunology, 2007, 179, 7397-7405.	0.4	64
58	Immunologically Active Autoantigens: The Role of Toll-Like Receptors in the Development of Chronic Inflammatory Disease. Annual Review of Immunology, 2007, 25, 419-441.	9.5	357
59	Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nature Immunology, 2007, 8, 487-496.	7.0	1,210
60	Tolling for Autoimmunity—Prime Time for 7. Immunity, 2006, 25, 397-399.	6.6	17
61	Toll-like receptors in systemic autoimmune disease. Nature Reviews Immunology, 2006, 6, 823-835.	10.6	988
62	DNA and RNA autoantigens as autoadjuvants. Journal of Endotoxin Research, 2006, 12, 379-384.	2.5	16
63	Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunological Reviews, 2005, 204, 27-42.	2.8	368
64	RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. Journal of Experimental Medicine, 2005, 202, 1171-1177.	4.2	730
65	Toll-like Receptor 9–Dependent and –Independent Dendritic Cell Activation by Chromatin–Immunoglobulin G Complexes. Journal of Experimental Medicine, 2004, 199, 1631-1640.	4.2	476
66	Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. Journal of Endotoxin Research, 2004, 10, 247-251.	2.5	36
67	The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity. Rheumatic Disease Clinics of North America, 2004, 30, 559-574.	0.8	24
68	Activation of Autoreactive B Cells by CpG dsDNA. Immunity, 2003, 19, 837-847.	6.6	492
69	Membrane Fas Ligand Activates Innate Immunity and Terminates Ocular Immune Privilege. Journal of Immunology, 2002, 169, 2727-2735.	0.4	80
70	Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature, 2002, 416, 603-607.	13.7	1,767
71	Sp1 is the majorfaslgene activator in abnormal CD4-CD8-B220+ T cells oflprandgldmice. European Journal of Immunology, 2001, 31, 3339-3348.	1.6	10
72	Fas Ligand Engagement of Resident Peritoneal Macrophages In Vivo Induces Apoptosis and the Production of Neutrophil Chemotactic Factors. Journal of Immunology, 2001, 167, 6217-6224.	0.4	142

#	Article	IF	CITATIONS
73	Protection of T cells from activation-induced cell death by Fas+ B cells. European Journal of Immunology, 2000, 30, 931-937.	1.6	13
74	Double mutant MRL-lpr/lpr-gld/gld cells fail to trigger lpr-graft-versus-host disease in syngeneic wild-type recipient mice, but can induce wild-type B cells to make auto-antibody. European Journal of Immunology, 2000, 30, 1778-1784.	1.6	8
75	TRAIL expression in vascular smooth muscle. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L1045-L1050.	1.3	55
76	Opposing Effects of Transmembrane and Soluble FAS Ligand Expression on Inflammation and Tumor Cell Survival. Journal of Experimental Medicine, 2000, 191, 1209-1220.	4.2	215
77	Immune Complexes Present in the Sera of Autoimmune Mice Activate Rheumatoid Factor B Cells. Journal of Immunology, 2000, 165, 1626-1633.	0.4	72
78	FasL promoter activation by IL-2 through SP1 and NFAT but not Egr-2 and Egr-3. European Journal of Immunology, 1999, 29, 3456-3465.	1.6	55
79	Unique site of IgG2a and rheumatoid factor production in MRL/lpr mice. Immunological Reviews, 1997, 156, 103-110.	2.8	21
80	Fas (CD95)/Fas ligand interactions regulate antigen-specific, major histocompatibility complex-restricted T/B cell proliferative responses. European Journal of Immunology, 1996, 26, 415-419.	1.6	41
81	The effect of VH residues 6 and 23 on IgG3 cryoprecipitation and glomerular deposition. European Journal of Immunology, 1995, 25, 279-284.	1.6	29
82	Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature, 1995, 373, 444-448.	13.7	1,485
83	Resistance to lymphoid engraftment inlpr recipients of normal bone marrow: characterization of chimeric stem cell, monocyte and peripheral lymphoid lineages. European Journal of Immunology, 1990, 20, 1917-1925.	1.6	3
84	Isolation of self-recognizing IgG2a monoclonal rheumatoid factors. Clinical Immunology and Immunopathology, 1989, 52, 313-322.	2.1	4
85	Oligoclonality of rheumatoid factors arising spontaneously in lpr/lpr mice. Clinical Immunology and Immunopathology, 1988, 46, 382-395.	2.1	51